Cargando…

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

Multiple myeloma (MM) is the main indication for autologous stem cell transplantation (ASCT). Novel supportive therapies (e.g., granulocyte colony-stimulating factor) have significantly improved post-ASCT-related mortality; however, data on biosimilar pegfilgrastim-bmez (BIO/PEG) in this setting is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, Pitino, Annalisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281896/ https://www.ncbi.nlm.nih.gov/pubmed/37079070 http://dx.doi.org/10.1007/s00277-023-05228-z

Ejemplares similares

Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation
por: Martino, Massimo, et al.
Publicado: (2023)

The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic
por: Canale, Filippo A., et al.
Publicado: (2023)

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
por: Loteta, Barbara, et al.
Publicado: (2021)

Thalidomide and discoid lupus erythematosus: case series and review of literature
por: Malara, Giovanna, et al.
Publicado: (2022)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

The Role of MicroRNA in Graft-Versus-Host-Disease: A Review
por: Pitea, Martina, et al.
Publicado: (2023)

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
por: Martino, Massimo, et al.
Publicado: (2021)

Biosimilar Pegfilgrastim-cbqv Demonstrated Similar Immunogenicity to Pegfilgrastim in Healthy Subjects Across Three Randomized Clinical Studies
por: Civoli, Francesca, et al.
Publicado: (2022)

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim
por: Kang, Ka‐Won, et al.
Publicado: (2020)

Pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
por: Wessels, Hendrik, et al.
Publicado: (2019)

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial
por: Wynne, Chris, et al.
Publicado: (2020)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg(®), a pegfilgrastim biosimilar in healthy subjects
por: Roth, Karsten, et al.
Publicado: (2019)

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure
por: Cornes, Paul, et al.
Publicado: (2020)

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma
por: Cerchione, Claudio, et al.
Publicado: (2022)

Meta‐analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim
por: Gattu, Sreekanth, et al.
Publicado: (2021)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim
por: Desai, Kalpna, et al.
Publicado: (2016)

A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®)
por: Wong, Gina, et al.
Publicado: (2020)

Relapsing Acute Kidney Injury Associated with Pegfilgrastim
por: Arora, Swati, et al.
Publicado: (2012)

PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta(®)): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
por: Moosavi, Shahrzad, et al.
Publicado: (2020)

Structural similarity, characterization of Poly Ethylene Glycol linkage and identification of product related variants in biosimilar pegfilgrastim
por: Shekhawat, Rakesh, et al.
Publicado: (2019)

Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study
por: Wang, Ching-Yu, et al.
Publicado: (2023)

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
por: Martino, Massimo, et al.
Publicado: (2022)

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
por: Desai, Kalpna, et al.
Publicado: (2018)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Cyclophosphamide/docetaxel/pegfilgrastim: Various toxicities: case report
Publicado: (2021)

Evaluation of a novel medical device for pegfilgrastim administration
por: Aruga, Tomoyuki, et al.
Publicado: (2022)

Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
por: Larrarte-González, María Alejandra, et al.
Publicado: (2023)

Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
por: Harbeck, Nadia, et al.
Publicado: (2016)

Analytical sameness methodology for the evaluation of structural, physicochemical, and biological characteristics of Armlupeg: A pegfilgrastim biosimilar case study
por: Deshmukh, Arati, et al.
Publicado: (2023)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
por: Kahan, Zsuzsanna, et al.
Publicado: (2019)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia
por: Guglielmelli, Tommasina, et al.
Publicado: (2009)

Long-Term Changes in Sleep Disordered Breathing in Renal Transplant Patients: Relevance of the BMI
por: Mallamaci, Francesca, et al.
Publicado: (2020)

Safety of Pegfilgrastim (Neulasta) in Patients with Sickle Cell Trait/Anemia
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2013)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5u54qbqt1vdicu1tcqoi534uq3